0001209191-20-048263.txt : 20200825
0001209191-20-048263.hdr.sgml : 20200825
20200825171603
ACCESSION NUMBER: 0001209191-20-048263
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200824
FILED AS OF DATE: 20200825
DATE AS OF CHANGE: 20200825
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hoelscher Paul W.
CENTRAL INDEX KEY: 0001611468
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35238
FILM NUMBER: 201133233
MAIL ADDRESS:
STREET 1: 520 LAKE COOK ROAD, SUITE 520
STREET 2: C/O HORIZON PHARMA, INC.
CITY: DEERFIELD
STATE: IL
ZIP: 60062
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Horizon Therapeutics Public Ltd Co
CENTRAL INDEX KEY: 0001492426
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: L2
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: CONNAUGHT HOUSE, 1ST FLOOR
STREET 2: 1 BURLINGTON ROAD
CITY: DUBLIN
STATE: L2
ZIP: 4
BUSINESS PHONE: 011-353-1-772-2100
MAIL ADDRESS:
STREET 1: CONNAUGHT HOUSE, 1ST FLOOR
STREET 2: 1 BURLINGTON ROAD
CITY: DUBLIN
STATE: L2
ZIP: 4
FORMER COMPANY:
FORMER CONFORMED NAME: Horizon Pharma plc
DATE OF NAME CHANGE: 20140919
FORMER COMPANY:
FORMER CONFORMED NAME: HORIZON PHARMA, INC.
DATE OF NAME CHANGE: 20100520
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-08-24
0
0001492426
Horizon Therapeutics Public Ltd Co
HZNP
0001611468
Hoelscher Paul W.
C/O HORIZON THERAPEUTICS PLC
CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD
DUBLIN
L2
4
IRELAND
0
1
0
0
EVP, CFO
Ordinary Shares
2020-08-24
4
S
0
27753
75.73
D
104748
I
By Trust
Ordinary Shares
2020-08-24
4
S
0
1823
76.23
D
102925
I
By Trust
Ordinary Shares
1049
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2020.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.13 to $76.11 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.18 to $76.54 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Includes 1,049 ordinary shares of the Issuer acquired by the reporting person on June 1, 2020 pursuant to an employee stock purchase program.
/s/ Miles W. McHugh, Attorney-in-Fact
2020-08-25